Elazzouzi Amy 4

What Happened
Amy Elazzouzi, Senior Vice President, Finance at Aura Biosciences (AURA), was granted a total of 125,000 shares on 2026-03-02 via two awards: 44,528 restricted stock units (RSUs) and 80,472 derivative-share awards. The filing reports an acquisition price of $0.00 per share (standard for equity grants). These are awards (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: 2026-03-02; Form 4 filed 2026-03-03 (appears timely).
• Grants: 44,528 RSUs (F1) and 80,472 derivative shares (F2) — total 125,000 shares. Reported price for both = $0.00.
• Vesting (from footnotes): RSUs vest in four substantially equal annual installments beginning Jan 15, 2027. The derivative award vests 25% on Feb 1, 2027, then pro rata monthly over 36 months thereafter, subject to continued service.
• Shares owned after transaction: not specified in the provided filing summary.
• No 10b5-1 plan, tax-withholding, or sale reported in this filing.

Context
These entries are grants/awards to an executive and reflect equity compensation with multi-year vesting—common for retention and incentive purposes. Because the awards vest over time, they are not immediately marketable shares. The filing shows acquisition via award (not a purchase or sale), so it should be read as compensation, not a direct bullish or bearish trade signal.